Last reviewed · How we verify
TAPINAROF
Tapinarof activates the aryl hydrocarbon receptor (AhR), but the exact mechanisms of its therapeutic effects are unknown.
At a glance
| Generic name | TAPINAROF |
|---|---|
| Drug class | Aryl Hydrocarbon Receptor Agonist [EPC] |
| Target | aryl hydrocarbon receptor (AhR) |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2022 |
Mechanism of action
Tapinarof is known to activate the aryl hydrocarbon receptor (AhR). However, the specific ways in which this activation leads to the therapeutic benefits of VTAMA cream are not fully understood.
Approved indications
Common side effects
- folliculitis
- nasopharyngitis
- contact dermatitis
- headache
- pruritus
- influenza
- upper respiratory tract infection
- folliculitis
- lower respiratory tract infection
- headache
- asthma
- vomiting
Key clinical trials
- A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis (PHASE3)
- Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma (PHASE2)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects (PHASE3)
- Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) (PHASE2, PHASE3)
- Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis (PHASE3)
- Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis (PHASE2)
- Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAPINAROF CI brief — competitive landscape report
- TAPINAROF updates RSS · CI watch RSS